Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus

References

• JevonsMPCoeAWParkerMTMethicillin resistance in staphylococciLancet19631904907
   PubMed Web of Science ®Google Scholar
• BoucherHWCoreyGREpidemiology of methicillin-resistant Staphylococcus aureusClin Infect Dis200846S344S34918462089
   PubMed Web of Science ®Google Scholar
• WallinTRHernHGFrazeeBWCommunity-associated methicillin-resistant Staphylococcus aureusEmerg Med Clin N Am200826431455
   PubMed Web of Science ®Google Scholar
• JohnsonLBSaravolatzLDCommunity-acquired MRSA: current epidemiology and management issuesInfect Med20052211620
   Google Scholar
• FileTMImpact of Community-associated methicillin-resistant Staphylococcus aureus in the hospital settingCleve Clin J Med200774S6S1117847173
   PubMedGoogle Scholar
• NaimiTSLeDellKHComo-SabettiKComparison of Community- and health care-associated methicillin-resistant Staphylococcus aureus infectionJAMA20032902976298414665659
   PubMed Web of Science ®Google Scholar
• Center for Disease Control MRSA definition reference http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca_clinicians.html#4. Accessed October 20, 2008.
   Google Scholar
• OtterJAFrenchGLNosocomial transmission of community-acquired methicillin-resistant Staphylococcus aureus: an emerging threatLancet Infect Dis2006675317123892
   PubMed Web of Science ®Google Scholar
• MareeCLDaumRSBoyle-VavraSCommunity-associated methicillin-resistant Staphylococcus aureus causing healthcare-associated infectionsEmerg Infect Dis20071323624217479885
   PubMed Web of Science ®Google Scholar
• DaumRSSkin and soft tissue infections caused by methicillin-resistant Staphylococcus aureusN Engl J Med200735738039017652653
   PubMed Web of Science ®Google Scholar
• GilletYVanhemsPLinaGFactors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidinClin Infect Dis20074531532117599308
   PubMed Web of Science ®Google Scholar
• GilletYIssartelBVanhemsPAssociation between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patientsLancet200235975375911888586
   PubMed Web of Science ®Google Scholar
• WeberJTCommunity-associated methicillin-resistant Staphylococcus aureusClin Infect Dis200541101373140616231249
   PubMed Web of Science ®Google Scholar
• MillerLGDiepBAColonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infectionsClin Infect Dis20084675276018220477
   PubMed Web of Science ®Google Scholar
• KazakovaSVHagemanJCMatavaMA clone of methicillin-resistant Staphylococcus aureus among professional football playersN Engl J Med200535246847515689585
   PubMed Web of Science ®Google Scholar
• SalgadoCDFarrBMCalfeeDPCommunity-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factorsClin Infect Dis200336213113912522744
   PubMed Web of Science ®Google Scholar
• WeberJTCommunity-associated methicillin-resistant Staphylococcus aureusClin Infect Dis200541S269S27216032563
   PubMed Web of Science ®Google Scholar
• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft-tissue infectionsClin Infect Dis200541101373140616231249
   PubMed Web of Science ®Google Scholar
• RuheJJSmithNBradsherRWCommunity onset of methicillin-resistant Staphylococcus aureus skin anad soft tissue infections: Impact of antimicrobial therapy outcomeClin Infect Dis20074477778417304447
   PubMed Web of Science ®Google Scholar
• GorwitzRJJerniganDBPowersJHStrategies for clinical management of MRSA in the community: Summary of an experts’ meeting convened by the Centers for Disease Control and Prevention2006 Available at http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html. 2006
   Google Scholar
• Septra® [package insert]. Bristol, TN, USA: King Pharmaceuticals; 2007
   Google Scholar
• KakaASRuedaAMShelburneSAIIIBactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureusJ Antimicrob Chemother20065868068316840428
   PubMed Web of Science ®Google Scholar
• MarkowitzNQuinnELSaravolatzKDTrimethoprim-Sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infectionsAnn Int Med19921173903981503330
   PubMed Web of Science ®Google Scholar
• SzumowskiJDChoenDEKanayaFTreatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinicAntimicrob Agents Chemother20075142342817116664
   PubMed Web of Science ®Google Scholar
• Cleocin® [package insert]. New York, NY, USA: Pfizer Inc; 2007
   Google Scholar
• DumitrescuOBoissetSBadrionCEffect of antibiotics on Staphylococcus aureus producing Panton-Valentine LeukocidinAntimicrob Agents Chemother2007511515151917242137
   PubMed Web of Science ®Google Scholar
• SiberryGKTekleTCarollKFailure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitroClin Infect Dis2003371257126014557972
   PubMed Web of Science ®Google Scholar
• PatelJBJevittLAHagemanJAn association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureusClin Infect Dis2006a421652165316652325
   PubMed Web of Science ®Google Scholar
• Vibramycin® [package insert]New York, NY, USAPfizer Inc2001
   Google Scholar
• Minocin® [package insert]Philadelphia, PA, USAWyeth Pharmaceuticals2005
   Google Scholar
• RuheJJMonsonTBradsherRWUse of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literatureClin Infect Dis200540101429143415844065
   PubMed Web of Science ®Google Scholar
• Sumycin® [package insert]Spring Valley, NY, USAPar Pharmaceuticals2006
   Google Scholar
• TenoverFCMcDougalLKGoeringRVCharacterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United StatesJ Clin Microbiol200644110811816390957
   PubMed Web of Science ®Google Scholar
• Zyvox® [package insert]New York, NY, USAPfizer Inc2008
   Google Scholar
• WeigeltJItaniKStevensDLinezolid versus vancomycin in treatment of complicated skin and soft tissue infectionsAntimicrob Agents Chemother2005171388416
   Google Scholar
• TsiodrasSGoldHSSakoulasGLinezolid resistance in a clinical isolate of Staphylococcus aureusLancet200135820720811476839
   PubMed Web of Science ®Google Scholar
• StevensDLMaYSalmiDBMcIndooEWallaceRJBryantAEImpact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureusJID200719520221117191165
   PubMed Web of Science ®Google Scholar
• StrausbaughLJJacobsonCSewellDLAntimicrobial therapy for methicillin-resistant Staphylococcus aureus colonization in residents and staff of a Veterans Affair nursing home care unitInfect Control Hosp Epidemiol19921331511591564313
   PubMed Web of Science ®Google Scholar
• Rifadin® [package insert]Bridgewater, NJ, USASanofi-aventis US LCC2007
   Google Scholar
• StryjewskiMEChambersHFSkin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureusClin Infect Dis200846S368S37718462092
   PubMed Web of Science ®Google Scholar
• HooperDCMechanisms of quinolone resistanceDrug Resistance Updates19992385511504468
   PubMed Web of Science ®Google Scholar
• TenoverFCMoelleringRCThe rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureusClin Infect Dis2007441208121517407040
   PubMed Web of Science ®Google Scholar
• Synercid® [package insert]Bristol, TN, USAMonarch Pharmaceuticals2003
   Google Scholar
• SaravolatzLDPawlakJJohnsonLBComparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureusJ Antimicrob Chemother200760240640917586562
   PubMed Web of Science ®Google Scholar
• MendesRESaderHSDeshpandeLAntimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylocoous aureus isolates recovered from North AmericaDiagn Microbiol Infect Dis200860443343618068326
   PubMed Web of Science ®Google Scholar
• NicholsRLGrahamDRBarriereSLTreatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection GroupJ Antimicrob Chemother199944226327310473234
   PubMed Web of Science ®Google Scholar
• MoelleringRCLindenPKReinhardtJThe efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study GroupJ Antimicrob Chemother199944225126110473233
   PubMed Web of Science ®Google Scholar
• Cubicin® [package insert]Lexington, MA, USACubist Pharmaceuticals2007
   Google Scholar
• JohnsonLBSaeedSPawlakJClinical and laboratory features of community-associated methicillin-resistant Staphylococcus aureus: is it really new?Infect Control Hosp Epidemiol200627213313816465629
   PubMed Web of Science ®Google Scholar
• CuiLTominagaENeohHMCorrelation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureusAntimicrob Agents Chemother2006501079108216495273
   PubMed Web of Science ®Google Scholar
• PatelMWaitesKBMoserSAPrevalence of inducible clindamycin resistance among community and hospital-associated Staphylococcus aureus isolatesJ Clin Microbiol2006b442481248216825368
   PubMed Web of Science ®Google Scholar
• SakoulasGAlderJThauvin-EliopoulosCInduction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycinAntimicrob Agents Chemother2006501581158516569891
   PubMed Web of Science ®Google Scholar
• PillaiSKGoldHSSakoulasGDaptomycin nonsusceptability in Staphylococcus aureus with reduced Vancomycin susceptibility is independent of alterations in MprFAntimicrob Agents Chermother20075122232226
   Web of Science ®Google Scholar
• ArbeitRDMakiDTallyFPDaptomycin 98–01 and 99–01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infectionsClin Infect Dis200438121673168115227611
   PubMed Web of Science ®Google Scholar
• FowlerVGJrBoucherHWCoreyGRDaptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureusN Engl J Med2006355765366516914701
   PubMed Web of Science ®Google Scholar
• KatzDEMartoneWJCommunity-phenotype-methicillin-resistant Staphylococcus aureus infections: a retrospective chart review of outcomes after treatment with daptomycinClin Ther200729112440244718158084
   PubMed Web of Science ®Google Scholar
• Tygacil® [package insert]Philadelphia, PA, USAWyeth Pharmaceuticals2007
   Google Scholar
• BreedtJTerasJGardovskisJTigecycline 305 c Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonamAntimicrob Agents Chemother200549114658466616251309
   PubMed Web of Science ®Google Scholar
• SacchidanandSPennRLEmbilJMEfficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trialInt J Infect Dis20059525126116099700
   PubMed Web of Science ®Google Scholar
• McAleeseFMurphyEBabinchakTUse of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolatesAntimicrob Agents Chemother200549114521452916251291
   PubMed Web of Science ®Google Scholar
• BaileyJSummersKMDalbavancin: a new lipoglycopeptide antibioticAm J Health Syst Pharm200865759961018359966
   PubMed Web of Science ®Google Scholar
• SeltzerEDorrMBGoldsteinBPDalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infectionsClin Infect Dis200337101298130314583862
   PubMed Web of Science ®Google Scholar
• JaureguiLEBabazadehSSeltzerERandomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infectionsClin Infect Dis200541101407141516231250
   PubMed Web of Science ®Google Scholar
• RaadIDarouicheRVazquezJEfficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogensClin Infect Dis200540337438015668859
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMWarrenYAIn vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infectionsAntimicrob Agents Chemother20065082875287916870792
   PubMed Web of Science ®Google Scholar
• AttwoodRJLaPlanteKLTelavancin: a novel lipoglycopeptide antimicrobial agentAm J Health Syst Pharm20076422233517989443
   PubMed Web of Science ®Google Scholar
• StryjewskiMEGrahamDRWilsonSEAssessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organismsClin Infect Dis200846111683169318444791
   PubMed Web of Science ®Google Scholar
• FowlerVGJrRudeTHNelsonCLActivity of telavancin against Staphylococcus aureus isolates carrying the Panton-Valentine leukocidin gene in the ATLAS studies [abstract 847]Program and abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases (Munich)2007
   Google Scholar
• PoulakouGGiamarellouHOritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogensExpert Opin Investig Drugs2008172225243
   PubMed Web of Science ®Google Scholar
• GiamarellouHO’RiordanWHarrisHPhase 3 trial comparing 3–7 days of oritavancin vs 10–14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (c) [abstract]Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago)Washington, DCAmerican Society for Microbiology2003
   Google Scholar
• WasilewskiMDishDMcGillJEquivalence of shorter course of therapy with oritavancin vs vancomycin/cephalexin in complicated skin and skin structure infections (c) [abstract UL-18]Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago)Washington, DCAmerican Society for Microbiology2001
   Google Scholar
• FluitACSchmitzFJVerhoefJSCCmec activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocciJ Antimicrob Chemother20025027127612161411
   PubMed Web of Science ®Google Scholar
• McKeeEEFergusonMBentleyATInhibition of mammalian mitochondrial protein synthesis by oxazolidinonesAntimicrob Agent and Chemo200650620422049
   PubMed Web of Science ®Google Scholar
• ChungMAntignacAKimCComparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-sepctrum cephalosporin ceftobiproleAntimicrob Agents Chemother20085282709271718505853
   PubMed Web of Science ®Google Scholar
• FritscheTRSaderHSJonesRNAntimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY antimicrobial surveillance program (2005–2006)Diag Microb Infect Dis2008618695
   PubMed Web of Science ®Google Scholar
• SaderHSFritscheTRJonesRNAntimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20085231153115518180353
   PubMed Web of Science ®Google Scholar
• LoTSWelchJMAlontoAMA review of the carbapenems in clinical use and clinical trialsRecent Patents Anti-Infect Drug Disc200832123131
   Google Scholar
• BradyALoughlinRGilpinDIn vitro activity of tea-tree oil against clinical skin isolates of methicillin-resistant and sensitive Staphylococcus aureus and coagulase-negative staphylococci growing planktonically and as biofilmsJ Medical Microbiol20065513751380
   PubMed Web of Science ®Google Scholar
• DrydenMSDaillySCrouchMA randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonizationJ Hosp Infect20045628328615066738
   PubMed Web of Science ®Google Scholar
• McMahonMABlairIMooreJHabituation to sub-lethal concentrations of tea tree oil (Melaleuca alternifolia) is associated with reduced susceptibility to antibiotics in human pathogensJ Antimicrob Chemother20075912512717071952
   PubMed Web of Science ®Google Scholar
• HanLMcDougalLGorwitzRHigh frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health centerJ Clin Microbiol2007451350135217287335
   PubMed Web of Science ®Google Scholar
• DiepBAChambersHFGrabersCJEmergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with menAnn Intern Med2008148424925718283202
   PubMed Web of Science ®Google Scholar
• MoranGJKrishnadasanAGorwitzRJMethicillin-resistant Staphylococcus aureus infections among patients in the emergency departmentN Engl J Med200635566667416914702
   PubMed Web of Science ®Google Scholar
• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft-tissue infectionsClin Infect Dis200541101373140616231249
   PubMed Web of Science ®Google Scholar
• Abbott. Sterile vancomycin hydrochloride, USP ADD-Vantage® vials prescribing informationNorth Chicago, IL1998
   Google Scholar
• CrumNFLeeRUThorntonSAFifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureusAm J Med20061191194395117071162
   PubMed Web of Science ®Google Scholar
• FridkinSKHagemanJCMorrisonMActive Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communitiesN Engl J Med2005352141436144415814879
   PubMed Web of Science ®Google Scholar
• HuangHFlynnNMKingJHComparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, CaliforniaJ Clin Microbiol20064472423242716825359
   PubMed Web of Science ®Google Scholar
• KingMDHumphreyBJWangYFEmergence of community-acquired methicillin-resistant Staphylococcus aureus USA300 clone as the predominant cause of skin and soft-tissue infectionsAnn Intern Med2006144530931716520471
   PubMed Web of Science ®Google Scholar
• NaimiTSLeDellKHBoxrudDJEpidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996–1998Clin Infect Dis200133799099611528570
   PubMed Web of Science ®Google Scholar
• TsujiBTRybakMJCheungCMCommunity- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agentsDiagn Microbiol Infect Dis2007581414717300912
   PubMed Web of Science ®Google Scholar